The global hypoxia inducible factor alpha inhibitor market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). Hypoxia-inducible factors (HIFs) are transcript factors responding to reductions in presented oxygen in the cellular environment or hypoxia. The major factor driving the growth of the market is the increasing prevalence of cancer across the globe. According to the National Cancer Institute (NCI), it was estimated that 1,806,590 new cases of cancer will be diagnosed in the US with a mortality rate of 606,520 people in 2020. Furthermore, there were 18.1 million new cases and 9.5 million cancer-related mortalities globally in 2018 which is anticipated to rise to 29.5 million and the number of cancer-related mortalities to 16.4 million by 2040. Hence, the rising prevalence of cancer is driving the demand for hypoxia inducible factor alpha inhibitors. The HIF-alpha is a major regulator of tumor angiogenesis. Histone deacetylase (HDAC) and Mammalian target of rapamycin (mTOR) inhibitors suppress tumor-induced angiogenesis by reducing tumor HIF-1 alpha protein expression.

Some major players operating in the market include Merck & Co., Inc., and Astellas Pharma Inc., among others. The market players are contributing significantly to the growth of the market by the adoption of various strategies including mergers & acquisitions, geographical expansion, partnerships and collaborations, and new product launches, to stay competitive in the market. For instance, in August 2021, Merck announced the approval of WELIREG from the US Food and Drug Administration (FDA). It is an oral hypoxia-inducible factor-2 alpha (HIF-2?) inhibitor that is used for the treatment of adult patients with von Hippel-Lindau (VHL) disease.

Market Coverage

• The market number available for – 2020-2027

• Base year- 2020

• Forecast period- 2021-2027

• Segment Covered- 

o By Type

o By Application

• Regions Covered-

o North America

o Europe

o Asia-Pacific

o Rest of the World

• Competitive Landscape- Merck & Co., Inc., and Astellas Pharma Inc., among others.

Key questions addressed by the report

• What is the market growth rate?

• Which segment and region dominate the market in the base year?

• Which segment and region will project the fastest growth in the market?

• How has COVID-19 impacted the market?

o Deviation from the pre-COVID-19 forecast

o Most affected region and segment

• Who is the leader in the market?

• How players are addressing challenges to sustain growth?

• Where is the investment opportunity?

Global Hypoxia Inducible Factor Alpha Inhibitor Market Report by Segment

By Type

• HIF-1?
• HIF-2?
• HIF-3?

By Application

• Solid Tumor
• Acute Myelocytic Leukemia
• Cancer
• Others

Global Hypoxia Inducible Factor Alpha Inhibitor Market Report by Region

North America

• United States

• Canada

Europe

• UK

• Germany

• Italy

• Spain

• France

• Rest of Europe 

Asia-Pacific

• China

• India

• Japan

• South Korea

• Rest of Asia-Pacific 

Rest of the World

• Latin America 

• Middle East & Africa